Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
22 mars 2021 04h00 HE
|
Vaccitech Limited
OXFORD, United Kingdom, March 22, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
18 mars 2021 03h00 HE
|
Vaccitech Limited
OXFORD, United Kingdom, March 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines...
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
17 mars 2021 03h00 HE
|
Vaccitech Limited
OXFORD, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Appoints Two Independent Board Directors
02 mars 2021 03h00 HE
|
Vaccitech Limited
OXFORD, United Kingdom, March 02, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd., a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
01 févr. 2021 03h00 HE
|
Vaccitech Limited
OXFORD, United Kingdom, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines...
Oxford University breakthrough on global COVID-19 vaccine
23 nov. 2020 03h23 HE
|
Vaccitech Limited
OXFORD, United Kingdom, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Vaccitech’s scientific founders at University of Oxford announce positive high-level results from an interim analysis of clinical trials of...